- Home
- PRZO vs NRSN Comparison
PRZO vs NRSN Comparison
Compare PRZO & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRZO
- NRSN
- Stock Information
- Founded
- PRZO 2014
- NRSN 2017
- Country
- PRZO Israel
- NRSN Israel
- Employees
- PRZO N/A
- NRSN N/A
- Industry
- PRZO
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- PRZO
- NRSN Health Care
- Exchange
- PRZO Nasdaq
- NRSN Nasdaq
- Market Cap
- PRZO 32.3M
- NRSN 29.8M
- IPO Year
- PRZO 2023
- NRSN 2021
- Fundamental
- Price
- PRZO $1.40
- NRSN $1.20
- Analyst Decision
- PRZO
- NRSN Buy
- Analyst Count
- PRZO 0
- NRSN 2
- Target Price
- PRZO N/A
- NRSN $14.00
- AVG Volume (30 Days)
- PRZO 966.5K
- NRSN 192.2K
- Earning Date
- PRZO 08-28-2025
- NRSN 12-17-2025
- Dividend Yield
- PRZO N/A
- NRSN N/A
- EPS Growth
- PRZO N/A
- NRSN N/A
- EPS
- PRZO N/A
- NRSN N/A
- Revenue
- PRZO $1,007,440.00
- NRSN N/A
- Revenue This Year
- PRZO N/A
- NRSN N/A
- Revenue Next Year
- PRZO N/A
- NRSN N/A
- P/E Ratio
- PRZO N/A
- NRSN N/A
- Revenue Growth
- PRZO 80.42
- NRSN N/A
- 52 Week Low
- PRZO $0.53
- NRSN $0.80
- 52 Week High
- PRZO $3.16
- NRSN $2.60
- Technical
- Relative Strength Index (RSI)
- PRZO 49.38
- NRSN 60.16
- Support Level
- PRZO $1.16
- NRSN $0.89
- Resistance Level
- PRZO $1.31
- NRSN $0.97
- Average True Range (ATR)
- PRZO 0.09
- NRSN 0.08
- MACD
- PRZO 0.01
- NRSN 0.02
- Stochastic Oscillator
- PRZO 71.79
- NRSN 100.00
About PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.